Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon SA, Desager JP, Desante KA, Frye RF, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y.
Chalon SA, et al. Among authors: thomasson hr.
Clin Pharmacol Ther. 2003 Mar;73(3):178-91. doi: 10.1067/mcp.2003.25.
Clin Pharmacol Ther. 2003.
PMID: 12621383